Astrozen Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 9 Year, 6 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 1.00 M
as on 17-12-2024
- Revenue %
(FY 2017)
- Profit -21.63%
(FY 2017)
- Ebitda 83.20%
(FY 2017)
- Net Worth -666.53%
(FY 2017)
- Total Assets 1.22%
(FY 2017)
About Astrozen Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.00 M.
Kaushilya Bharti, Indra Bharti, and Lallan Singh serve as directors at the Company.
- CIN/LLPIN
U24233MH2015PTC265367
- Company No.
265367
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Jun 2015
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Astrozen Pharmaceuticals Private Limited offer?
Astrozen Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs.
Who are the key members and board of directors at Astrozen Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Indra Bharti  | Director | 09-Jun-2015 | Current |
| Kaushilya Bharti | Director | 09-Jun-2015 | Current |
| Lallan Singh | Director | 11-Aug-2023 | Current |
Financial Performance of Astrozen Pharmaceuticals.
Astrozen Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 21.63% decrease in profit. The company's net worth observed a substantial decline by a decrease of 666.53%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Astrozen Pharmaceuticals?
In 2017, Astrozen Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Advanced Fms And Security Services Private LimitedActive 11 years 7 monthsLallan Singh is a mutual person
- Prisah Fms And Security Services (Opc) Private LimitedActive 4 years 1 month
Lallan Singh is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 24 Nov 2020 | ₹1.00 M | Open |
How Many Employees Work at Astrozen Pharmaceuticals?
Unlock and access historical data on people associated with Astrozen Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Astrozen Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Astrozen Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
